\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
New York, NY and Tel Aviv, ISRAEL, Aug. 1, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and similar response company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the previous publication in ResearchGate of a case study titled “Tollovid as a rescue agent for Paxlovid rebound in acute COVID-19” supervised by Dr. Lee Morgentaler in conjunction with Andrew A. Blumenthal, RN ADS of a patient with post-acute COVID sequelae (PASC, or “Long COVID”) who underwent multiple reinfections with the SARS-CoV-2 virus over 27 months and experienced a complete solution of COVID symptoms. within 5 days. Paxlovid® remedy after positive PCR after which the patient immediately felt a COVID rebound that resolved after eating supplements with the 3CL immune-aided nutritional supplement inhibitor Tollovid ™ proteaseArrayPrepublication can be found at: https://www. researchgate. net/publ ication/362387662_Tollovid_as_Rescue_Agent_for_Paxlovid_Rebound_in_Acute_Covid-19Array
SUMMARY
The existing outbreak of COVID-19 caused by the new SARS-CoV-2 virus remains a global emergency. According to the CDC, the primary form of treatment for mild to moderate COVID-19 is Paxlovid, an oral antiviral compound of nirmatrelvir and Ritonavir. However, patients reported the following positive viral antigens and recurrence of COVID-19 symptoms within 2 to 8 days of the end of their recommended 5-day treatment of Paxlovid. Here we describe a case of SARS-CoV-2 reinfection in a prolonged COVID patient treated with Paxlovid. The subject reported rebound symptoms without delay after completing a 5-day cycle of Paxlovid. solution of acute symptoms of COVID.
To purchase Tollovid, visit Amazon or www. MyTollovid. com.
About Tollovid® and Tollovid Daily™
Tollovid and Tollovid Daily are oral nutritional supplements made with herbal ingredients that aid and maintain a healthy immune system and also have resistant 3CL protease inhibiting properties based on in vitro activity tests that show strong inhibition of 3CL protease activity. Tollovid’s 3CL binding affinity The IC50 protease is at least ten times (10x) more potent than the binding affinity of the 3CL IC50 protease published through Ivermectin. The IC50 binding affinity of Tollovid Daily’s 3CL protease is at least two and a half times (2. 5x) that of ivermectin. and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with four doses of 3 pills taken each day to provide the maximum immune systemArrayTollovid Daily is a daily immune product with two daily dosing regimens. Preliminary data from an ongoing study on the IRB exemption of consumers who have used the products to help with their COVID and Long COVID was recently announced.
To purchase Tollovid, visit Amazon or www. MyTollovid. com.
About Tollovir®
Tollovir® is an oral 3CL protease inhibitor and an anti-cytokine curative candidate for Nidovirus organization intervention that includes coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollvir is made from herbal ingredients qualified to achieve strong inhibition of 3CL protease in vitro, as well as strong anti-cytokine activity. Tollvir has effectively completed a Phase 2 clinical trial in Israel for the remedy of hospitalized patients with COVID-19. the remedy of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-distance COVID, and potentially pediatric COVID-19. All have authorized the rights of Tollvir to T-Cell Protect Hellas S. A. for the Greek market.
About All Medical Ltd.
Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs important diagnostic solutions for the early detection of various types of cancer. The company’s proprietary infrared biochemical analyses (TBIs) are a patented generation of cancer detection that employs peripheral blood research that examines the influence of cancer on the immune system, looking for biochemical adjustments in blood mononuclear cells and plasma. All recently acquired the medical diagnostic company founded in the US. USA Provided Diagnostics, Inc. to secure the rights of its qualified CLIA/CAP laboratory founded in Alpharetta, Georgia, which is lately conducting COVID PCR testing and Provista’s patented Videssa® breast cancer blood test provided at the advertising stage.
All are also performing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. Lymphocyte Proliferation Control (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to be exogenous mitogens. stimulation that activates them to enter the mobile cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised mobile machinery leading to aberrant re-entry of the mobile cycle through neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a replacement for neuronal mobile function, suggesting a non-unusual dating between PBLs and neurons in the brain.
All formed the Israel-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March 2022 to consolidate all intellectual assets pursuing the progression of diagnostic tests targeting 3CL protease, as well as botanical protease inhibitors and 3CL prescription drugs that target a basic reproductive mechanism of coronaviruses. 3CL Pharma, through the Brand Todos, has marketed the immune nutritional supplement protease inhibitor 3CL Tollovid® in the United States, is introducing the dual-mechanism 3CL protease inhibitor and the anti-cytokine curative drug candidate Tollvir ®, while also presenting the 3CL protease inhibitor TolloTest™ diagnosis.
For more information, visit https://www. todosmedical. com/.
Forward-Looking Statements
Certain statements contained in this press release may possibly constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical trials and clinical progression systems. These forward-looking statements are based solely on existing control expectations and are subject to vital dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding dangers and uncertainties related to the ProgressArray. timing, loading and effects of clinical trials and product progression systems; difficulties or delays in discharging regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to release more mandatory budget to carry out our research, development and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments to generation and market requirements; delays or obstacles in starting our clinical trials; adjustments in the legislation; failure to expand and introduce new technologies, products and programs in a timely manner; lack of validation of our generation as we move forward and lack of acceptance of our strategies throughout the clinical community; inability to retain or attract key workers whose wisdom is essential to the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; final product load higher than expected; loss of market share percentage and pressure on charges resulting from the festival; and laboratory effects that do not translate to similar intelligent effects under actual conditions, which may also cause actual effects or functionality to differ materially from those implied by such forward-looking statements. Except as otherwise required by law, Todos Medical assumes no legal responsibility to publish revisions to such forward-looking statements to reflect events or events after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the dangers and uncertainties affecting Todos Medical, please refer to its reports filed periodically with the United States Securities and Exchange Commission.
Company Contact:
daniel hirsch
Chief Financial Officer
all doctor
917-983-4229 extension 104
Dan. h@todosmedical. com